Heterogeneous immunological recovery trajectories revealed in post-acute COVID-19
Author:
Su Yapeng,Yuan Dan,Chen Daniel G.,Wang Kai,Choi Jongchan,Dai Chengzhen L.,Hong Sunga,Zhang Rongyu,Xie Jingyi,Li Sarah,Scherler Kelsey,Pavlovitch-Bedzyk Ana Jimena,Dong Shen,Lausted Christopher,Ng Rachel H.,Lee Inyoul,Fallen Shannon,Kornilov Sergey A.,Baloni Priyanka,Duvvuri Venkata R.,Anderson Kristin G.,Li Jing,Yang Fan,Rostomily Clifford,Troisch Pamela,Smith Brett,Zhou Jing,Mackay Sean,Murray Kim,Edmark Rick,Jones Lesley,Zhou Yong,Rowen Lee,Liu Rachel,Chour William,Berrington William R.,Wallick Julie A,Algren Heather A,Wrin Terri,Petropoulos Christos J.,Wei Wei,Price Nathan D.,Subramanian Naeha,Hadlock Jennifer,Magis Andrew T.,Ribas Antoni,Lanier Lewis L.,Boyd Scott D.,Bluestone Jeffrey A.,Hood Leroy,Gottardo Raphael,Greenberg Philip D.,Davis Mark M.,Goldman Jason D.,Heath James R.,
Abstract
AbstractThe immunological picture of how different patients recover from COVID-19, and how those recovery trajectories are influenced by infection severity, remain unclear. We investigated 140 COVID-19 patients from diagnosis to convalescence using clinical data, viral load assessments, and multi-omic analyses of blood plasma and circulating immune cells. Immune-phenotype dynamics resolved four recovery trajectories. One trajectory signals a return to pre-infection healthy baseline, while the other three are characterized by differing fractions of persistent cytotoxic and proliferative T cells, distinct B cell maturation processes, and memory-like innate immunity. We resolve a small panel of plasma proteins that, when measured at diagnosis, can predict patient survival and recovery-trajectory commitment. Our study offers novel insights into post-acute immunological outcomes of COVID-19 that likely influence long-term adverse sequelae.
Publisher
Cold Spring Harbor Laboratory
Reference65 articles.
1. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study 2. Long-term health consequences of COVID-19;JAMA,2020 3. Management of post-acute covid-19 in primary care 4. Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19;Cell,2020 5. J. Schulte-Schrepping , N. Reusch , D. Paclik , K. Baßler , S. Schlickeiser , B. Zhang , B. Krämer , T. Krammer , S. Brumhard , L. Bonaguro , E. De Domenico , D. Wendisch , M. Grasshoff , T. S. Kapellos , M. Beckstette , T. Pecht , A. Saglam , O. Dietrich , H. E. Mei , A. R. Schulz , C. Conrad , D. Kunkel , E. Vafadarnejad , C.-J. Xu , A. Horne , M. Herbert , A. Drews , C. Thibeault , M. Pfeiffer , S. Hippenstiel , A. Hocke , H. Müller-Redetzky , K.-M. Heim , F. Machleidt , A. Uhrig , L. Bosquillon de Jarcy , L. Jürgens , M. Stegemann , C. R. Glösenkamp , H.-D. Volk , C. Goffinet , M. Landthaler , E. Wyler , P. Georg , M. Schneider , C. Dang-Heine , N. Neuwinger , K. Kappert , R. Tauber , V. Corman , J. Raabe , K. M. Kaiser , M. T. Vinh , G. Rieke , C. Meisel , T. Ulas , M. Becker , R. Geffers , M. Witzenrath , C. Drosten , N. Suttorp , C. von Kalle , F. Kurth , K. Händler , J. L. Schultze , A. C. Aschenbrenner , Y. Li , J. Nattermann , B. Sawitzki , A.-E. Saliba , L. E. Sander , A. Angelov , R. Bals , A. Bartholomäus , A. Becker , D. Bezdan , E. Bonifacio , P. Bork , T. Clavel , M. Colome-Tatche , A. Diefenbach , A. Dilthey , N. Fischer , K. Förstner , J.-S. Frick , J. Gagneur , A. Goesmann , T. Hain , M. Hummel , S. Janssen , J. Kalinowski , R. Kallies , B. Kehr , A. Keller , S. Kim-Hellmuth , C. Klein , O. Kohlbacher , J. O. Korbel , I. Kurth , M. Landthaler , Y. Li , K. Ludwig , O. Makarewicz , M. Marz , A. McHardy , C. Mertes , M. Nöthen , P. Nürnberg , U. Ohler , S. Ossowski , J. Overmann , S. Peter , K. Pfeffer , A. R. Poetsch , A. Pühler , N. Rajewsky , M. Ralser , O. Rieß , S. Ripke , U. Nunes da Rocha , P. Rosenstiel , A.-E. Saliba , L. E. Sander , B. Sawitzki , P. Schiffer , E.-C. Schulte , J. L. Schultze , A. Sczyrba , O. Stegle , J. Stoye , F. Theis , J. Vehreschild , J. Vogel , M. von Kleist , A. Walker , J. Walter , D. Wieczorek , J. Ziebuhr , Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell (2020), doi:https://doi.org/10.1016/j.cell.2020.08.001.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|